A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

RECRUITING

Monash Health - Monash Medical Centre /ID# 272234, Clayton

RECRUITING

Icon Cancer Centre Chermside /ID# 272220, Chermside

RECRUITING

CHA Bundang Medical Center /ID# 271590, Seongnam

RECRUITING

Seoul National University Bundang Hospital /ID# 271594, Seongnam-si

RECRUITING

Allegheny Health Network West Penn Hospital /ID# 272267, Pittsburgh

RECRUITING

First Physicians Group /ID# 272180, Sarasota

RECRUITING

St. Elizabeth Medical Center - Edgewood /ID# 272113, Edgewood

RECRUITING

Keimyung University Dongsan Hospital /ID# 271592, Daegu

RECRUITING

Karmanos Cancer Institute - Detroit /ID# 272112, Detroit

RECRUITING

UMass Memorial Medical Center /ID# 272122, Worcester

RECRUITING

Seoul National University Hospital /ID# 272264, Seoul

RECRUITING

Yonsei University Health System Severance Hospital /ID# 271593, Seoul

RECRUITING

Asan Medical Center /ID# 272130, Seoul

RECRUITING

Gangnam Severance Hospital /ID# 272217, Seoul

RECRUITING

Samsung Medical Center /ID# 271591, Seoul